Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/02/2874637/20739/en/Ultragenyx-Reports-First-Quarter-2024-Financial-Results-and-Corporate-Update.html
https://www.globenewswire.com/news-release/2024/04/30/2872737/20739/en/Ultragenyx-Issues-2023-Corporate-Responsibility-Report-Showcasing-Commitment-to-Improving-Equity-and-Access-to-Innovation-in-Rare-Disease.html
https://www.globenewswire.com/news-release/2024/04/30/2872207/20739/en/Ultragenyx-Announces-Completion-of-Enrollment-in-Phase-3-Orbit-and-Cosmic-Studies-Evaluating-Setrusumab-UX143-for-the-Treatment-of-Osteogenesis-Imperfecta-OI.html
https://www.globenewswire.com/news-release/2024/04/25/2870100/20739/en/Ultragenyx-to-Host-Conference-Call-for-First-Quarter-2024-Financial-Results-and-Corporate-Update.html
https://www.globenewswire.com/news-release/2024/04/19/2866376/20739/en/Ultragenyx-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.biopharmadive.com/news/ultragenyx-angelman-gtx-102-interim-results/713169/
https://www.globenewswire.com/news-release/2024/04/12/2862138/20739/en/Ultragenyx-Announces-Upcoming-Data-Presentations-at-American-Academy-of-Neurology-AAN-2024-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/03/22/2851131/20739/en/Ultragenyx-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com//news-release/2024/02/27/2836492/20739/en/Ultragenyx-to-Participate-at-Investor-Conferences-in-March.html
https://www.globenewswire.com//news-release/2024/02/23/2834646/20739/en/Ultragenyx-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html